713 results on '"Roughead, Elizabeth E"'
Search Results
102. Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial).
- Author
-
Roughead, Elizabeth E, Pratt, Nicole L, Parfitt, Gaynor, Rowett, Debra, Kalisch-Ellett, Lisa M, Bereznicki, Luke, Merlin, Tracy, Corlis, Megan, Kang, Ai Choo, Whitehouse, Joseph, Bilton, Rebecca, Schubert, Camille, Torode, Stacey, Kelly, Thu-Lan, Andrade, Andre Q, Post, Dannielle, Dorj, Gereltuya, Cousins, Justin, Williams, Mackenzie, and Lim, Renly
- Subjects
- *
PREVENTION of drug side effects , *OCCUPATIONAL roles , *RESEARCH , *COGNITION disorders , *GRIP strength , *PARASYMPATHOMIMETIC agents , *BODY weight , *CONFIDENCE intervals , *POLYPHARMACY , *MOVEMENT disorders , *NURSING care facilities , *MEDICATION therapy management , *RANDOMIZED controlled trials , *ACCELEROMETRY , *QUALITY of life , *DESCRIPTIVE statistics , *STATISTICAL sampling - Abstract
Objective To assess the effectiveness of a pharmacist-led intervention using validated tools to reduce medicine-induced deterioration and adverse reactions. Design and setting Multicenter, open-label parallel randomised controlled trial involving 39 Australian aged-care facilities. Participants Residents on ≥4 medicines or ≥1 anticholinergic or sedative medicine. Intervention Pharmacist-led intervention using validated tools to detect signs and symptoms of medicine-induced deterioration which occurred every 8 weeks over 12 months. Comparator Usual care (Residential Medication Management Review) provided by accredited pharmacists. Outcomes Primary outcome was change in Frailty Index at 12 months. Secondary outcomes included changes in cognition, 24-hour movement behaviour by accelerometry, grip strength, weight, adverse events and quality of life. Results 248 persons (median age 87 years) completed the study; 120 in the interventionand, 128 in control arms. In total 575 pharmacist, sessions were undertaken in the intervention arm. There was no statistically significant difference for change in frailty between groups (mean difference: 0.009, 95% CI: −0.028, 0.009, P = 0.320). A significant difference for cognition was observed, with a mean difference of 1.36 point change at 12 months (95% CI: 0.01, 2.72, P = 0.048). Changes in 24-hour movement behaviour, grip strength, adverse events and quality of life were not significantly different between groups. Point estimates favoured the intervention arm at 12 months for frailty, 24-hour movement behaviour and grip strength. Conclusions The use of validated tools by pharmacists to detect signs of medicine-induced deterioration is a model of practice that requires further research, with promising results from this trial, particularly with regards to improved cognition. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
103. Prescriber Feedback to Improve Quality Use of Medicines among Older People: the Veteransʼ MATES Program
- Author
-
Bell, Simon J, Kalisch, Lisa M, Ramsay, Emmae N, Pratt, Nicole L, Barratt, John D, LeBlanc, Tammy, Roughead, Elizabeth E, and Gilbert, Andrew L
- Published
- 2011
104. Major bleeding risk associated with warfarin and co-medications in the elderly population
- Author
-
Vitry, Agnes I., Roughead, Elizabeth E., Ramsay, Emmae N., Preiss, Adrian K., Ryan, Philip, Gilbert, Andrew L., Caughey, Gillian E., Shakib, Sepehr, Esterman, Adrian, Zhang, Ying, and McDermott, Robyn A
- Published
- 2011
- Full Text
- View/download PDF
105. Ageing well: Improving the management of patients with multiple chronic health problems
- Author
-
Gilbert, Andrew L, Caughey, Gillian E, Vitry, Agnes I, Clark, Alice, Ryan, Philip, McDermott, Robyn A, Shakib, Sepehr, Luszcz, Mary A, Esterman, Adrian, and Roughead, Elizabeth E
- Published
- 2011
- Full Text
- View/download PDF
106. Multimorbidity, care complexity and prescribing for the elderly
- Author
-
Roughead, Elizabeth E, Vitry, Agnes I, Caughey, Gillian E, and Gilbert, Andrew L
- Published
- 2011
- Full Text
- View/download PDF
107. Improvement in metformin and insulin utilisation in the Australian veteran population associated with quality use of medicines intervention programs
- Author
-
Gadzhanova, Svetla, Roughead, Elizabeth E., Loukas, Katrina, and Vajda, Jacqualine
- Published
- 2011
- Full Text
- View/download PDF
108. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing?†
- Author
-
Caughey, Gillian E., Roughead, Elizabeth E., Pratt, Nicole, Shakib, Sepehr, Vitry, Agnes I., and Gilbert, Andrew L.
- Published
- 2010
- Full Text
- View/download PDF
109. Prevalence of potentially hazardous drug interactions amongst Australian veterans
- Author
-
Roughead, Elizabeth E., Kalisch, Lisa M., Barratt, John D., and Gilbert, Andrew L.
- Published
- 2010
- Full Text
- View/download PDF
110. Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments†
- Author
-
Pratt, Nicole, Roughead, Elizabeth E., Ryan, Philip, and Salter, Amy
- Published
- 2010
- Full Text
- View/download PDF
111. Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates†
- Author
-
Roughead, Elizabeth E., Ramsay, Emmae, Priess, Kym, Barratt, John, Ryan, Philip, and Gilbert, Andrew L.
- Published
- 2009
- Full Text
- View/download PDF
112. Medication‐related hospital admissions in aged care residents.
- Author
-
Kalisch Ellett, Lisa M., Kassie, Gizat M., Caughey, Gillian E., Pratt, Nicole L., Ramsay, Emmae N., and Roughead, Elizabeth E.
- Subjects
CLINICAL drug trials ,KEY performance indicators (Management) ,RETROSPECTIVE studies ,HOSPITAL care ,RESIDENTIAL care ,CLINICAL medicine ,ACCIDENTAL falls ,RESEARCH funding ,DRUG side effects ,PATIENT compliance ,MEDICAL care of veterans ,HEART failure ,OLD age - Abstract
Objective: To determine the prevalence of medication‐related hospitalisations preceded by potentially suboptimal processes of care in aged care residents. Method: We conducted a retrospective analysis of administrative claims data from the Australian Government Department of Veterans' Affairs (DVA). We identified all hospital admissions for aged care residents between 1 July 2014 and 30 June 2019. The proportion of hospital admissions preceded by potentially suboptimal medication‐related processes of care was determined. Results: A total of 18 874 hospitalisations were included, and 46% were preceded by potentially suboptimal medication‐related care. One‐quarter of fracture admissions occurred in residents at risk of fracture who were not using a medicine to prevent fracture, and 87% occurred in residents using falls‐risk medicines. Thirty per cent of heart failure admissions occurred in patients who were not using an angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker. Conclusion: Nearly half of hospital admissions were preceded by potentially suboptimal medication‐related processes of care. Interventions to improve use of medicines for aged care residents in these areas are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
113. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia†
- Author
-
Hynd, Anna, Roughead, Elizabeth E., Preen, David B., Glover, John, Bulsara, Max, and Semmens, James
- Published
- 2008
- Full Text
- View/download PDF
114. Validity of Medication-Based Comorbidity Indices in the Australian Elderly Population: 200.
- Author
-
Vitry, Agnes I, Wong, Soo Ann, Roughead, Elizabeth E, and Ramsay, Emmae
- Published
- 2008
- Full Text
- View/download PDF
115. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia†,‡
- Author
-
Kalisch, Lisa M., Roughead, Elizabeth E., Sci, App M, Gilbert, Andrew L., and Psych, Dip App
- Published
- 2008
- Full Text
- View/download PDF
116. Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes
- Author
-
Roughead, Elizabeth E., Pratt, Nicole, and Gilbert, Andrew L.
- Published
- 2007
117. Enhancing early uptake of drug evidence into primary care
- Author
-
Roughead, Elizabeth E
- Published
- 2006
- Full Text
- View/download PDF
118. Magnetic Resonance Imaging in People With Cardiac Implantable Electronic Devices: A Population Based Cohort Study
- Author
-
Gillam, Marianne H., Inacio, Maria C.S., Pratt, Nicole L., Shakib, Sepehr, and Roughead, Elizabeth E.
- Published
- 2018
- Full Text
- View/download PDF
119. Chapter 15 - Strengths and Weaknesses of Pharmaceutical Policy in Relation to Rational and Responsible Medicines Use
- Author
-
Nguyen, Tuan A. and Roughead, Elizabeth E.
- Published
- 2018
- Full Text
- View/download PDF
120. Heart failure after conventional metal-on-metal hip replacements
- Author
-
Gillam, Marianne H, Pratt, Nicole L, Inacio, Maria C S, Roughead, Elizabeth E, Shakib, Sepehr, Nicholls, Stephen J, and Graves, Stephen E
- Subjects
musculoskeletal diseases ,Aged, 80 and over ,Heart Failure ,Male ,Hip ,Arthroplasty, Replacement, Hip ,Incidence ,Australia ,Prosthesis Design ,Prosthesis Failure ,Survival Rate ,Metal-on-Metal Joint Prostheses ,Humans ,Female ,Hip Prosthesis ,Registries ,Aged ,Follow-Up Studies ,Retrospective Studies - Abstract
Background and purpose — It is unclear whether metal particles and ions produced by mechanical wear and corrosion of hip prostheses with metal-on-metal (MoM) bearings have systemic adverse effects on health. We compared the risk of heart failure in patients with conventional MoM total hip arthroplasty (THA) and in those with metal-on-polyethylene (MoP) THA. Patients and methods — We conducted a retrospective cohort study using data from the Australian Government Department of Veterans’ Affairs health claims database on patients who received conventional THA for osteoarthritis between 2004 and 2012. The MoM THAs were classified into groups: Articular Surface Replacement (ASR) XL Acetabular System, other large-head (LH) (> 32 mm) MoM, and small-head (SH) (≤ 32 mm) MoM. The primary outcome was hospitalization for heart failure after THA. Results — 4,019 patients with no history of heart failure were included (56% women). Men with an ASR XL THA had a higher rate of hospitalization for heart failure than men with MoP THA (hazard ratio (HR) = 3.2, 95% CI: 1.6–6.5). No statistically significant difference in the rate of heart failure was found with the other LH MoM or SH MoM compared to MoP in men. There was no statistically significant difference in heart failure rate between exposure groups in women. Interpretation — An association between ASR XL and hospitalization for heart failure was found in men. While causality between ASR XL and heart failure could not be established in this study, it highlights an urgent need for further studies to investigate the possibility of systemic effects associated with MoM THA.
- Published
- 2016
121. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review
- Author
-
Pratt Nicole, Roughead Elizabeth E, Salter Amy, and Ryan Philip
- Subjects
Antipsychotics ,Review ,Death ,Cerebrovascular events ,Stroke ,Hip fracture ,Pneumonia ,Hospitalisation ,Medicine (General) ,R5-920 - Abstract
Abstract Background Antipsychotics are frequently and increasingly prescribed to treat the behavioural symptoms associated with dementia despite their modest efficacy. Evidence regarding the potential adverse events of antipsychotics is limited and little is known about the longer-term safety of these medicines in the elderly. The aim of this review was to determine the impact of the choice of observational study design and methods used to control for confounding on the measurement of antipsychotic risks in elderly patients. Methods We searched PUBMED and the Cochrane controlled trials register for double-blind randomised controlled trials (RCTs), meta-analyses and published observational studies of antipsychotics. Results Forty four studies were identified for the endpoints; death, cerebrovascular events, hip fracture and pneumonia. RCTs found a 20% to 30% increased risk of death, or an absolute increase of 1extra death per 100 patients with atypical antipsychotics compared to non-use. Cohort and instrumental variable analyses estimated between 2 to 7 extra deaths per 100 patients with conventional compared to atypical antipsychotics. RCTs found a 2 to 3 times increased risk of all cerebrovascular events with atypical antipsychotics compared to placebo and no association with serious stroke that required hospitalisation. Observational studies using cohort and self-controlled case-series designs reported similar results; no association where the endpoint was stroke causing hospitalisation and a doubling of risk when minor stroke was included. No RCTs were available for the outcome of hip fracture or pneumonia. Observational studies reported a 20% to 40% increased risk of hip fracture with both antipsychotic classes compared to non-use. The risk of pneumonia was a 2 to 3 times greater with both classes compared to non-use while a self-controlled case-series study estimated a 60% increased risk. Conventional antipsychotics were associated with a 50% greater hip fracture risk than atypical antipsychotics, while the risk of pneumonia was similar between the classes. Conclusions Choice of observational study design is critical in studying the adverse effects of antispychotics. Cohort and instrumental variable analyses gave more consistent results to clinical studies for mortality outcomes as have self-controlled case-series for the risk of cerebrovascular events and stroke. Observational evidence has highlighted the potential for antipsychotics to be associated with serious adverse events that were not reported in RCTs including hip fracture and pneumonia. Good quality observational studies are required, that employ appropriate study designs that are robust towards unmeasured confounding, to confirm the potential excess risk of hip fracture and pneumonia with antipsychotics.
- Published
- 2012
- Full Text
- View/download PDF
122. A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly
- Author
-
Pratt Nicole L, Ewald Ben, Roughead Elizabeth E, Ramsay Emmae N, and Ryan Philip
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background To determine the suitability of using the self-controlled case series design to assess improvements in health outcomes using the effectiveness of beta blockers for heart failure in reducing hospitalisations as the example. Methods The Australian Government Department of Veterans' Affairs administrative claims database was used to undertake a self-controlled case-series in elderly patients aged 65 years or over to compare the risk of a heart failure hospitalisation during periods of being exposed and unexposed to a beta blocker. Two studies, the first using a one year period and the second using a four year period were undertaken to determine if the estimates varied due to changes in severity of heart failure over time. Results In the one year period, 3,450 patients and in the four year period, 12, 682 patients had at least one hospitalisation for heart failure. The one year period showed a non-significant decrease in hospitalisations for heart failure 4-8 months after starting beta-blockers, (RR, 0.76; 95% CI (0.57-1.02)) and a significant decrease in the 8-12 months post-initiation of a beta blocker for heart failure (RR, 0.62; 95% CI (0.39, 0.99)). For the four year study there was an increased risk of hospitalisation less than eight months post-initiation and significant but smaller decrease in the 8-12 month window (RR, 0.90; 95% CI (0.82, 0.98)). Conclusions The results of the one year observation period are similar to those observed in randomised clinical trials indicating that the self-controlled case-series method can be successfully applied to assess health outcomes. However, the result appears sensitive to the study periods used and further research to understand the appropriate applications of this method in pharmacoepidemiology is still required. The results also illustrate the benefits of extending beta blocker utilisation to the older age group of heart failure patients in which their use is common but the evidence is sparse.
- Published
- 2011
- Full Text
- View/download PDF
123. Use of health services and medicines amongst Australian war veterans: a comparison of young elderly, near centenarians and centenarians
- Author
-
Ryan Philip, Ramsay Emmae N, Kalisch Lisa M, Roughead Elizabeth E, and Gilbert Andrew L
- Subjects
Geriatrics ,RC952-954.6 - Abstract
Abstract Background Age and life expectancy of residents in many developed countries, including Australia, is increasing. Health resource and medicine use in the very old is not well studied. The purpose of this study was to identify annual use of health services and medicines by very old Australian veterans; those aged 95 to 99 years (near centenarians) and those aged 100 years and over (centenarians). Methods The study population included veterans eligible for all health services subsidised by the Department of Veterans' Affairs (DVA) aged 95 years and over at August 1st 2006. A cohort of veterans aged 65 to 74 years was identified for comparison. Data were sourced from DVA claims databases. We identified all claims between August 1st 2006 and July 31st 2007 for medical consultations, pathology, diagnostic imaging and allied health services, hospital admissions, number of prescriptions and unique medicines. Chi squared tests were used to compare the proportion of centenarians (those aged 100 years and over) and near centenarians (those aged 95 to 99 years) who accessed medicines and health services with the 65 to 74 year age group. For those who accessed health services during follow up, Poisson regression was used to compare differences in the number of times centenarians and near centenarians accessed each health service compared to 65 to 74 year olds. Results A similar proportion (98%) of centenarians and near centenarians compared to those aged 65 to 74 consulted a GP and received prescription medicine during follow up. A lower proportion of centenarians and near centenarians had claims for specialist visits (36% and 57% respectively), hospitalisation (19% and 24%), dental (12% and 18%), physiotherapy (13% and 15%), pathology(68% and 78%) and diagnostic imaging services (51% and 68%) (p < 0.0001) and a higher proportion had claims for care plans (19% and 25%), occupational therapy (15% and 17%) and podiatry services (54% and 58%) (p < 0.0001). Compared to those aged 65 to 74, a lower proportion of centenarians and near centenarians received antihypertensives, lipid lowering therapy, antiinflammatories, and antidepressants (p < 0.0001) and a higher proportion received antibiotics, analgesics, diuretics, laxatives, and anti-anaemics (p < 0.0001). Conclusions Medical consultations and medicines are the health services most frequently accessed by Australian veteran centenarians and near centenarians. For most health services, the proportion of very old people who access them is similar to or less than younger elderly. Our results support the findings of other studies which suggest that longevity is not necessarily associated with excessive health service use.
- Published
- 2010
- Full Text
- View/download PDF
124. Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia
- Author
-
Ismail Shaiful B, Roughead Elizabeth E, Vitry Agnes I, Othman Noordin, and Omar Khairani
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in Malaysia and no recent evidence in Australia is present. We aimed to compare the provision of medicines information by pharmaceutical representatives to doctors in Australia and Malaysia. Methods Following a pharmaceutical representative's visit, general practitioners in Australia and Malaysia who had agreed to participate, were asked to fill out a questionnaire on the main product and claims discussed during the encounter. The questionnaire focused on provision of product information including indications, adverse effects, precautions, contraindications and the provision of information on the Pharmaceutical Benefit Scheme (PBS) listings and restrictions (in Australia only). Descriptive statistics were produced. Chi-square analysis and clustered linear regression were used to assess differences in Australia and Malaysia. Results Significantly more approved product information sheets were provided in Malaysia (78%) than in Australia (53%) (P < 0.001). In both countries, general practitioners reported that indications (Australia, 90%, Malaysia, 93%) and dosages (Australia, 76%, Malaysia, 82%) were frequently provided by pharmaceutical representatives. Contraindications, precautions, drug interactions and adverse effects were often omitted in the presentations (range 25% - 41%). General practitioners in Australia and Malaysia indicated that in more than 90% of presentations, pharmaceutical representatives partly or fully answered their questions on contraindications, precautions, drug interactions and adverse effects. More general practitioners in Malaysia (85%) than in Australia (60%) reported that pharmaceutical representatives should have mentioned contraindications, precautions for use, drug interaction or adverse effects spontaneously (P < 0.001). In 48% of the Australian presentations, general practitioners reported the pharmaceutical representatives failed to mention information on PBS listings to general practitioners. Conclusions Information on indications and dosages were usually provided by pharmaceutical representatives in Australia and Malaysia. However, risk and harmful effects of medicines were often missing in their presentations. Effective control of medicines information provided by pharmaceutical representatives is needed.
- Published
- 2010
- Full Text
- View/download PDF
125. Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States
- Author
-
Vitry Agnes I, Othman Noordin, and Roughead Elizabeth E
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. The quality of claims, references and the presentation of risk results in Australia and the US has been questioned in several studies. No recent evidence is available on the quality of claims, references and the presentation of risk results in journal advertising in Australia and the US and no Malaysian data have been published. The aim of this study was to compare the quality of claims, references and the presentation of risk results in journal advertising in these three countries. Methods A consecutive sample of 85 unique advertisements from each country was selected from journal advertising published between January 2004 to December 2006. Claims, references and the presentation of risk results in medical journal advertising were compared between the three countries. Results Less than one-third of the claims were unambiguous claims (Australia, 30%, Malaysia 17%, US, 23%). In Malaysia significantly less unambiguous claims were provided than in Australia and the US (P < 0.001). However, the unambiguous claims were supported by more references than other claims (80%). Most evidence was obtained from at least one randomized controlled trial, a systematic review or meta-analysis (Australia, 84%, Malaysia, 81%, US, 76%) with journal articles being the most commonly cited references in all countries. Data on file were significantly more likely to be cited in the US (17%) than in Australia (2%) and Malaysia (4%) (P < 0.001). Advertisements that provided quantitative information reported risk results exclusively as a relative risk reduction Conclusions The majority of claims were vague suggesting poor quality of claims in journal advertising in these three countries. Evidence from a randomized controlled trial, systematic review or meta- analysis was commonly cited to support claims. However, the more frequent use of data that have not been published and independently reviewed in the US compared to Australia and Malaysia raises questions on the quality of references in the US. The use of relative rather than absolute benefits may overemphasize the benefit of medicines which may leave doctors susceptible to misinterpreting information.
- Published
- 2010
- Full Text
- View/download PDF
126. Prevalence of comorbidity of chronic diseases in Australia
- Author
-
Roughead Elizabeth E, Gilbert Andrew L, Vitry Agnes I, and Caughey Gillian E
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background The prevalence of comorbidity is high, with 80% of the elderly population having three or more chronic conditions. Comorbidity is associated with a decline in many health outcomes and increases in mortality and use of health care resources. The aim of this study was to identify, review and summarise studies reporting the prevalence of comorbidity of chronic diseases in Australia. Methods A systematic review of Australian studies (1996 – May 2007) was conducted. The review focused specifically on the chronic diseases included as national health priorities; arthritis, asthma, cancer, cardiovascular disease (CVD), diabetes mellitus and mental health problems. Results A total of twenty five studies met our inclusion criteria. Over half of the elderly patients with arthritis also had hypertension, 20% had CVD, 14% diabetes and 12% mental health problem. Over 60% of patients with asthma reported arthritis as a comorbidity, 20% also had CVD and 16% diabetes. Of those with CVD, 60% also had arthritis, 20% diabetes and 10% had asthma or mental health problems. Conclusion There are comparatively few Australian studies that focused on comorbidity associated with chronic disease. However, they do show high prevalence of comorbidity across national health priority areas. This suggests integration and co-ordination of the national health priority areas is critical. A greater awareness of the importance of managing a patients' overall health status within the context of comorbidity is needed together with, increased research on comorbidity to provide an appropriate scientific basis on which to build evidence based care guidelines for these multimorbid patients.
- Published
- 2008
- Full Text
- View/download PDF
127. Use of health and support services by people living with dementia in the community setting.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Nguyen, Tuan A., and Roughead, Elizabeth E.
- Subjects
MEDICAL care for older people ,DEMENTIA ,HEALTH services accessibility ,RESEARCH methodology ,MEDICAL care ,MEDICINE ,COMMUNITY services ,INDEPENDENT living ,CROSS-sectional method ,RETROSPECTIVE studies ,DESCRIPTIVE statistics - Abstract
Objective: To determine the access to and use of health‐care services by people with dementia in the community. Methods: A retrospective cross‐sectional analysis of the Australian Government Department of Veterans' Affairs (DVA) administrative claims data was conducted. Veterans and their spouses with one or more dementia claims between 1 January 2000 and 30 June 2016, who were aged ≥45 years at the time of the claim and who were still alive and living in the community on 30 June 2017, were included. We assessed the proportions of people with dementia who received medical, pharmacy and medicines, allied health services, and home care supports from 1 July 2016 to 30 June 2017. Results: A total of 10 171 people with dementia were included. They had a median age of 89 years, 60% were female, and 63% lived in a major city. Over the one‐year study period, 98% visited the GP and 99% had medicines dispensed at a pharmacy. Eighty‐two per cent saw a specialist, and 19% saw a geriatrician. Thirty‐one per cent received a DVA‐funded dose administration aid to support medication administration, and 19% received a home medicines review. Less than half had claims for occupational therapist services (48%), community nursing (48%), physiotherapists (41%) or dentist visits (33%). Fifty‐eight per cent received home care supports, for example domestic assistance. Conclusions: Many people living with dementia in the community do not access all of the health‐care or support services available to them. Ensuring that people with dementia and their carers are supported to access the services available to assist them live in the community setting for as long as possible is important. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
128. Consumer involvement in Quality Use of Medicines (QUM) projects – lessons from Australia
- Author
-
Monteith Gregory R, Roughead Elizabeth E, Kirkpatrick Carl MJ, and Tett Susan E
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background It is essential that knowledge gained through health services research is collated and made available for evaluation, for policy purposes and to enable collaboration between people working in similar areas (capacity building). The Australian Quality Use of Medicine (QUM) on-line, web-based project database, known as the QUMmap, was designed to meet these needs for a specific sub-section of health services research related to improving the use of medicines. Australia's National Strategy for Quality Use of Medicines identifies the primacy of consumers as a major principle for quality use of medicines, and aims to support consumer led research. The aim of this study was to determine how consumers as a group have been represented in QUM projects in Australia. A secondary aim was to investigate how the projects with consumer involvement fit into Australia's QUM policy framework. Method Using the web-based QUMmap, all projects which claimed consumer involvement were identified and stratified into four categories, projects undertaken by; (a) consumers for consumers, (b) health professionals for consumers, (c) health professionals for health professionals, and (d) other. Projects in the first two categories were then classified according to the policy 'building blocks' considered necessary to achieve QUM. Results Of the 143 'consumer' projects identified, the majority stated to be 'for consumers' were either actually by health professionals for health professionals (c) or by health professionals for consumers (b) (47% and 40% respectively). Only 12 projects (9%) were directly undertaken by consumers or consumer groups for consumers (a). The majority of the health professionals for consumers (b) projects were directed at the provision of services and interventions, but were not focusing on the education, training or skill development of consumers. Conclusion Health services research relating to QUM is active in Australia and the projects are collated and searchable on the web-based interactive QUMmap. Healthcare professionals appear to be dominating nominally 'consumer focussed' research, with less than half of these projects actively involving the consumers or directly benefiting consumers. The QUMmap provides a valuable tool for policy analysis and for provision of future directions through identification of QUM initiatives.
- Published
- 2005
- Full Text
- View/download PDF
129. Towards the development of Vietnam's national dementia plan—the first step of action.
- Author
-
Nguyen, Tuan Anh, Pham, Thang, Dang, Thu Ha, Hinton, Walter Ladson, Nguyen, Anh Trung, Pham, Tuan Le, Crotty, Maria, Kurrle, Susan, Bui, Quang Thuc, Nguyen, Huong, and Roughead, Elizabeth E.
- Subjects
CONFERENCES & conventions ,INTERPROFESSIONAL relations ,NATIONAL health services ,POLICY sciences ,PUBLIC health ,SOCIAL support ,HUMAN services programs ,STAKEHOLDER analysis - Abstract
Objective: To foster a national dialogue on addressing dementia as an emerging public health problem and formulating a strategy for developing Vietnam's national dementia plan. Methods: In September 2018, the Vietnamese National Geriatric Hospital supported by University staff in Australia and the United States organised the first Vietnam National Dementia Conference in Hanoi. Results: Over 270 Vietnamese dementia stakeholders and international dementia experts participated in the conference. The participants agreed dementia was a public health priority in Vietnam and identified the need for the development of Vietnam's national dementia plan. Policymakers supported positioning dementia as a priority in the national health agenda. Research institutions created collaboration to generate scientific information for policymaking process. Funding and international supports were obtained to develop Vietnam's national dementia plan. Conclusion: Strong leadership, stakeholder engagement and international support are critical in raising awareness and advocating for the development of Vietnam's national dementia plan. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
130. Frequent general practitioner visits are protective against statin discontinuation after a Pharmaceutical Benefits Scheme copayment increase.
- Author
-
Seaman, Karla L., Sanfilippo, Frank M., Bulsara, Max K., Brett, Tom, Kemp-Casey, Anna, Roughead, Elizabeth E., Bulsara, Caroline, and Preen, David B.
- Subjects
CHI-squared test ,CONFIDENCE intervals ,PHARMACEUTICAL services insurance ,LONGITUDINAL method ,MEDICAL appointments ,MEDICAL care costs ,HEALTH policy ,MEDICARE ,MULTIVARIATE analysis ,PREVENTIVE health services ,PRIMARY health care ,QUESTIONNAIRES ,RESEARCH funding ,STATISTICS ,STATINS (Cardiovascular agents) ,LOGISTIC regression analysis ,DATA analysis ,RETROSPECTIVE studies ,DATA analysis software ,ONE-way analysis of variance - Abstract
Objective: This study assessed the effect of the frequency of general practitioner (GP) visitation in the 12 months before a 21% consumer copayment increase in the Pharmaceutical Benefits Scheme (PBS; January 2005) on the reduction or discontinuation of statin dispensing for tertiary prevention. Methods: The study used routinely collected, whole-population linked PBS, Medicare, mortality and hospital data from Western Australia. From 2004 to 2005, individuals were classified as having discontinued, reduced or continued their use of statins in the first six months of 2005 following the 21% consumer copayment increase on 1 January 2005. The frequency of GP visits was calculated in 2004 from Medicare data. Multivariate logistic regression models were used to determine the association between GP visits and statin use following the copayment increase. Results: In December 2004, there were 22 495 stable statin users for tertiary prevention of prior coronary heart disease, prior stroke or prior coronary artery revascularisation procedure. Following the copayment increase, patients either discontinued (3%), reduced (12%) or continued (85%) their statins. Individuals who visited a GP three or more times in 2004 were 47% less likely to discontinue their statins in 2005 than people attending only once. Subgroup analysis showed the effect was apparent in men, and long-term or new statin users. The frequency of GP visits did not affect the proportion of patients reducing their statin therapy. Conclusions: Patients who visited their GP at least three times per year had a lower risk of ceasing their statins in the year following the copayment increase. GPs can help patients maintain treatment following rises in medicines costs. What is known about the topic?: Following the 21% increase in medication copayment in 2005, individuals discontinued or reduced their statin usage, including for tertiary prevention. What does this paper add?: Patients who visited their GP at least three times per year were less likely to discontinue their statin therapy for tertiary prevention following a large copayment increase. What are the implications for practitioners?: This paper identifies the important role that GPs have in maintaining the continued use of important medications following rises in medicines costs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
131. Preventing overdoses with over‐the‐counter medicines.
- Author
-
Roughead, Elizabeth E and Lim, Renly
- Published
- 2023
- Full Text
- View/download PDF
132. Use of medicines that may precipitate delirium prior to hospitalisation in older Australians with delirium: An observational study.
- Author
-
Kassie, Gizat M., Kalisch Ellett, Lisa M., Nguyen, Tuan A., and Roughead, Elizabeth E.
- Subjects
DIAGNOSIS of delirium ,RISK of delirium ,VETERANS' societies ,ANTIDEPRESSANTS ,DRUG utilization ,HOSPITAL care ,MEDICATION errors ,NARCOTICS ,SCIENTIFIC observation ,RISK-taking behavior ,TRANQUILIZING drugs ,DISEASE prevalence ,RETROSPECTIVE studies ,OLD age - Abstract
Objective: To assess the use of medicines associated with delirium prior to hospital admission in older Australian patients with a recorded diagnosis of delirium. Methods: A retrospective observational study was conducted using de‐identified data from the Australian Government Department of Veterans' Affairs Health Care Claims Database. The prevalence of use of medicines associated with delirium was determined in people 65 years or older with a delirium diagnosis. Results: Three‐quarters of the total 22 923 older patients included were taking at least one medicine associated with delirium, the median number of medications per patient was two (interquartile range, 1‐3). The most frequently used medicines known to be associated with delirium were psycholeptics, opioids and tricyclic antidepressants. Conclusion: A substantial proportion of older hospitalised patients with a delirium diagnosis were taking medicines known or suspected to precipitate delirium prior to admission. There may be an opportunity to decrease medication‐associated delirium by reducing use of risky medication. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
133. Consumer-directed technologies to improve medication management and safety.
- Author
-
Andrade, Andre Q and Roughead, Elizabeth E
- Abstract
The article focuses on the consumer-directed technologies like electronic medication management systems, which have limited evidence and needs more evidence to prove its effectiveness and value.
- Published
- 2019
- Full Text
- View/download PDF
134. Mesh use in urogynaecological procedures between 2005 and 2016: An Australian cohort study.
- Author
-
Gillam, Marianne H., Kerr, Mhairi, Pratt, Nicole L., Lim, Renly, and Roughead, Elizabeth E.
- Subjects
PELVIC organ prolapse ,CONFIDENCE intervals ,UROLOGICAL surgery ,LONGITUDINAL method ,RESEARCH funding ,TIME series analysis ,URINARY stress incontinence ,LOGISTIC regression analysis ,DATA analysis software ,DESCRIPTIVE statistics ,SURGICAL meshes ,SURGERY - Abstract
Background: Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) are common conditions. The use of mesh in the surgical treatment of these conditions in Australia is unclear. Aim: To examine the use of mesh in POP and SUI procedures in an Australian national cohort of older women. Methods: We conducted a population‐based cohort study using data from the Australian Government Department of Veterans' Affairs (DVA) database. The cohort consisted of older women who had POP and SUI procedures between 1 July, 2005 and 31 December, 2016. Women who received mesh were identified by matching device billing codes with the Australian Government's Prosthesis List. Results: In total, 3129 women experienced 3472 hospitalisations for POP and SUI procedures, with 74% of the women aged 75 years and older. There were 2276 (66%) hospitalisations with single POP repairs, 608 (18%) with single SUI procedures and 588 (17%) with concomitant POP and SUI procedures. Mesh was used in 23% of single procedures for POP, in 89% of single procedures for SUI and in 90% of concomitant POP and SUI procedures. The use of mesh in POP procedures decreased from a peak of 33% in 2008 down to 8% by 2016, whereas the use of mesh in SUI procedures increased from 77% in 2006 to 91% by 2016. Conclusion: Mesh was commonly used in SUI procedures, whereas use of mesh in POP repair was less common and the use decreased rapidly after 2011, when warnings about use of mesh in POP were first issued. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
135. Comparative safety of NSAIDs for gastrointestinal events in Asia‐Pacific populations: A multi‐database, international cohort study.
- Author
-
Lai, Edward Chia‐Cheng, Shin, Ju‐Young, Kubota, Kiyoshi, Man, Kenneth K.C., Park, Byung Joo, Pratt, Nicole, Roughead, Elizabeth E., Wong, Ian C.K., Kao Yang, Yea‐Huei, and Setoguchi, Soko
- Abstract
Purpose The safety of nonsteroidal anti‐inflammatory drugs (NSAIDs) commonly used in Asia‐Pacific countries has had limited study. We assessed the risk of hospitalization for gastrointestinal events with loxoprofen and mefenamic acid compared with other NSAIDs in Asia‐Pacific populations. Methods: We conducted a cohort study using a distributed network with a common data model in Australia, Hong Kong, Japan, Korea, and Taiwan. We included patients who initiated diclofenac, loxoprofen, mefenamic acid, or celecoxib and followed them until their first gastrointestinal hospitalization, switch or discontinuation of medication, disenrollment, or end of database coverage. We used Cox proportional hazards models to assess hospitalization risk. Results: We identified 9879 patients in Japan, 70 492 in Taiwan, 263 741 in Korea, and 246 in Hong Kong who initiated an NSAID, and 44 013 patients in Australia, a predominantly Caucasian population. The incidence of gastrointestinal hospitalization was 25.6 per 1000 person‐years in Japan, 32.8 in Taiwan, 11.5 in Korea, 484.5 in Hong Kong, and 35.6 in Australia. Compared with diclofenac, the risk of gastrointestinal events with loxoprofen was significantly lower in Korea (hazards ratio, 0.37; 95% CI, 0.25‐0.54) but not in Japan (1.65; 95% CI, 0.47‐5.78). The risk of gastrointestinal events with mefenamic acid was significantly lower in Taiwan (0.45; 95% CI, 0.26‐0.78) and Korea (0.11; 95% CI, 0.05‐0.27) but not Hong Kong (2.16; 95% CI, 0.28‐16.87), compared with diclofenac. Conclusions: Compared with diclofenac, loxoprofen was associated with a lower risk of gastrointestinal hospitalizations in Korea and mefenamic acid with a lower risk in Taiwan and Korea. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
136. Rehospitalizations for complications and mortality following pacemaker implantation: A retrospective cohort study in an older population.
- Author
-
Gillam, Marianne H., Pratt, Nicole L., Inacio, Maria C. S., Shakib, Sepehr, Sanders, Prashanthan, Lau, Dennis H., and Roughead, Elizabeth E.
- Published
- 2018
- Full Text
- View/download PDF
137. ENGAGEMENT OF MULTI-STAKEHOLDERS FOR THE DEVELOPMENT OF VIETNAM’S NATIONAL DEMENTIA PLAN: LESSONS LEARNED FROM THE FIRST VIETNAM NATIONAL DEMENTIA CONFERENCE
- Author
-
Dang, Thu Ha, Nguyen, Tuan Anh, Pham, Thang, Hinton, Ladson, Nguyen, Trung Anh, Le Pham, Tuan, Crotty, Maria, Kurrle, Susan, Bui, Quang Thuc, Nguyen, Huong, and Roughead, Elizabeth E.
- Published
- 2019
- Full Text
- View/download PDF
138. Persistence with opioids post discharge from hospitalisation for surgery in an Australian adult cohort
- Author
-
Lim, Renly, Roughead, Elizabeth E., Ramsay, Emmae, Moffat, Anna, and Pratt, Nicole
- Published
- 2019
- Full Text
- View/download PDF
139. Proton-pump inhibitors and the risk of antibiotic use and hospitalization for pneumonia
- Author
-
Roughead, Elizabeth E., Ramsay, Emmae N., Pratt, Nicole L., Ryan, Philip, and Gilbert, Andrew L.
- Subjects
Proton pump inhibitors -- Usage ,Proton pump inhibitors -- Complications and side effects ,Bacterial pneumonia -- Drug therapy ,Bacterial pneumonia -- Care and treatment ,Pneumonia -- Drug therapy ,Pneumonia -- Care and treatment ,Hospital care -- Evaluation ,Health - Abstract
The study examines if proton-pump inhibitor (PPI) use is associated with hospitalizations for pneumonia and with antibiotic use. Results show PPI use is associated with a small, but significant, increased risk of antibiotic use and hospitalization for pneumonia, suggesting that the prevalent use of PPIs could be harmful.
- Published
- 2009
140. Managing adverse drug reactions: Time to get serious
- Author
-
Roughead, Elizabeth E.
- Subjects
Aged -- Health aspects ,Drugs -- Adverse and side effects ,Drugs -- Risk factors ,Drugs -- Prevention ,Health - Abstract
The rate of Adverse Drug Reactions (ADRs) associated with hospitalizations in people aged 60 years and over more than doubled between the years 1991 and 2002. Multidisciplinary approaches such as clinical pharmacy, hospital discharge planning and case conferencing services are found to be effective in reducing the adverse drug events.
- Published
- 2005
141. List of Contributors
- Author
-
Abdel Rida, Nada, Alfadl, Abubakr A., Ansari, Mukhtar, Arafat, Yara, Azhar, Saira, Babar, Zaheer-Ud-Din, Casadei, Gianluigi, Fang, Yu, Fathelrahman, Ahmed I., Fatokun, Omotayo, Hassali, Mohamed Azmi, Khanal, Saval, Kohler, Jillian C., Minghetti, Paola, Mohamed Ibrahim, Mohamed Izham, Moscou, Kathy, Ng, Chin H., Nguyen, Tuan A., Nissen, Lisa M., Njuguna, Benson, Ooi, Guat See, Palaian, Subish, Pastakia, Sonak, Paudyal, Vibhu, Poudel, Arjun, Shankar, Pathiyil Ravi, Roughead, Elizabeth E., Scahill, Shane L., Shafie, Asrul A., Thomas, Dixon, Tran, Dan N., Upadhyay, Dinesh K., Wertheimer, Albert I., Wong, Zhi Yen, Yan, Kangkang, Yusuff, Kazeem B., and Zachariah, Seeba
- Published
- 2018
- Full Text
- View/download PDF
142. The association between frailty and medicines use over time: an analysis using the Australian Longitudinal Study on Ageing population.
- Author
-
Widagdo, Imaina S., Pratt, Nicole L., and Roughead, Elizabeth E.
- Abstract
Background: Frailty and medicine‐related problems are common among the elderly and have been associated with an increased risk of adverse outcomes. However, there has been limited research on the association between frailty and medicines use. Aim: To determine the distribution of frailty among older people who used medicines and to examine the difference in frailty scores over time with continuation or discontinuation of specific medicines. Methods: The study population was from the Australian Longitudinal Study of Ageing (ALSA). The data used in the analysis were collected in 1992 (wave 1) and in 1995 (wave 3). Frailty scores were assessed at both waves using a modified version of the Frailty Index. Non‐parametric tests were used to examine the difference in the distribution of frailty scores in relation to medicines used at baseline. Medicine use was categorised into continued or stopped by comparing use at wave 3 to use at baseline. A t‐test was used to compare the mean changes in frailty scores between the two groups, with a p‐value of <0.05 considered to be significant. Results: Data from 2087 participants were included. At baseline, a higher number of medicines used was associated with higher frailty scores (p < 0.0001). Stopping any preventive medicines, as well as beta‐blockers, or potassium‐sparing diuretics, was associated with a higher increase in mean frailty score changes than continuing these medicines, p = 0.01, p = 0.03 and p = 0.004, respectively. Conclusions: There was an association between frailty and medicines use. Further study is needed to assess whether the progression of frailty was due to medicine cessation or vice versa. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
143. Use of medicines and health services for chronic obstructive pulmonary disease among a cohort of Australians over 50 years.
- Author
-
Lim, Renly, Kerr, Mhairi, and Roughead, Elizabeth E
- Published
- 2018
- Full Text
- View/download PDF
144. Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review.
- Author
-
Eng Whui Poh, McArthur, Alexa, Stephenson, Matthew, and Roughead, Elizabeth E.
- Published
- 2018
- Full Text
- View/download PDF
145. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
- Author
-
Roughead, Elizabeth E., Dong-Sook Kim, Ong, Benjamin, and Kemp-Casey, Anna
- Published
- 2018
- Full Text
- View/download PDF
146. Antidepressant switching patterns in the elderly.
- Author
-
Gadzhanova, Svetla, Roughead, Elizabeth E., and Pont, Lisa G.
- Abstract
ABSTRACTBackground:Switching between antidepressants is complex due to potential adverse outcomes such as serotonin syndrome and antidepressant discontinuation syndrome, yet switching is often required due to non-response to initial treatment. This study aimed to examine the patterns and extent of antidepressant switching in a cohort of older adults in long-term residential care.
Methods: A cohort study of medication supply data from 6011 aged care residents in 60 long-term care facilities was conducted. Incident antidepressant users were followed for 12 months and their patterns of antidepressant use determined. The type of switching from and to different antidepressant classes was determined according to National and International recommendations for antidepressant switching.Results: In total, 11% (n = 44) of the residents were initiated on an antidepressant medication (n = 402) switched to a different antidepressant agent within 12 months. Residents commenced on a SNRI or TCA were most likely to switch antidepressants (17% in each group). Almost half of the switches (n = 21, 48% of all switches) were not implemented according to guideline recommendations. Direct switch and taper followed by wash out and switch, accounted for all of the inappropriate switching (29% and 71%, respectfully), with half occurring to mirtazapine (N = 7) or from mirtazapine (N = 3).Conclusions: Over one in 10 long-term aged care residents who commence an antidepressant will switch to a different antidepressant within 12 months. Current antidepressant switching practices in long-term residential aged care may be increasing the risk of harm associated with antidepressant switching, with around half of all switches not following current guideline recommendations. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
147. Sustaining practice change in health care: the impact of a national quality improvement program on the uptake of collaborative medicines reviews.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Sluggett, Janet K., Ramsay, Emmae N., Kerr, Mhairi, LeBlanc, Vanessa T., Barratt, John D., Gilbert, Andrew L., and Roughead, Elizabeth E.
- Abstract
Abstract: Aim: We evaluated the impact of quality improvement interventions at different time points on the uptake of collaborative Home Medicines Reviews (HMRs). Methods: National interventions to promote HMRs, comprising patient‐specific prescriber feedback and tailored educational materials for patients and clinicians, were conducted in 2004, 2006 and 2011 through the Veterans’ Medicines Advice and Therapeutics Education Services (Veterans’ MATES) program. Primary care patients taking multiple medicines were targeted in each intervention, while primary care patients taking multiple medicines who did not receive the intervention served as comparisons. Monthly HMR rates among targeted patients and a comparison group in the 9 months post‐intervention were determined using health claims data from the Australian Government Department of Veterans’ Affairs and compared using log binomial regression models. Overall trends in the rate of HMRs between November 2001 and December 2016 were also determined. Results: Over 40 000 patients were targeted in each HMR intervention. Relative increases in HMR uptake were observed among patients targeted in the 2004 intervention (rate ratio (RR) 1.76 (1.39, 2.22), p < 0.0001), the 2006 intervention (RR 1.45 (1.19, 1.76), p = 0.0002) and the 2011 intervention (RR 2.81 (2.34, 3.37), p < 0.0001) compared to the comparison group. Overall, the monthly HMR rate increased from 0.2 per 1000 patients in November 2001 to 2.7 per 1000 patients in December 2012. Conclusion: Regular repetition of quality improvement messages has led to sustained increases in HMR uptake among Australian veterans over the last decade. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
148. Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts.
- Author
-
Bartlett, Louise E, Pratt, Nicole L, and Roughead, Elizabeth E
- Subjects
CARDIOVASCULAR agents ,COMBINATION drug therapy ,DRUG dosage ,ANTILIPEMIC agents ,ANTIHYPERTENSIVE agents - Abstract
Purpose: Many studies of persistence involving fixed dose combinations (FDCs) of cardiovascular medicines have not adequately accounted for a user's prior experience with similar medicines. The aim of this research was to assess the effect of prior medicine experience on persistence to combination therapy. Patients and methods: Two retrospective cohort studies were conducted in the complete Pharmaceutical Benefits Scheme prescription claims dataset. Initiation and cessation rates were determined for combinations of: ezetimibe/statin; and amlodipine/statin. Initiators to combinations of these medicines between April and September 2013 were classified according to prescriptions dispensed in the prior 12 months as either: experienced to statin or calcium channel blocker (CCB); or naïve to both classes of medicines. Cohorts were stratified according to formulation initiated: FDC or separate pill combinations (SPC). Cessation of therapy over 12 months was determined using Kaplan–Meier survival analysis. Risk of cessation, adjusted for differences in patient characteristics was assessed using Cox proportional hazard models. Results: There were 12,169 people who initiated combinations of ezetimibe/statin; and 26,848 initiated combinations of amlodipine/statin. A significant proportion of each cohort were naïve initiators: ezetimibe/statin cohort, 1,964 (16.1%) of whom 81.9% initiated a FDC; and amlodipine/statin cohort, 5,022 (18.7%) of whom 55.4% initiated a FDC. Naïve initiators had a significantly higher risk of ceasing therapy than experienced initiators regardless of formulation initiated: ezetimibe/statin cohort, naïve FDC versus experienced FDC HR=3.0 (95% CI 2.8, 3.3) and naïve SPC versus experienced SPC HR=4.4 (95% CI 3.8, 5.2); and amlodipine/statin cohort naïve FDC versus experienced FDC HR=2.0 (95% CI 1.8, 2.2) and naïve SPC versus experienced SPC HR=1.5 (95% CI 1.4,1.6). Conclusion: Prescribers are initiating people to combinations of two cardiovascular medicines without prior experience to at least one medicine in the combination. This is associated with a higher risk of ceasing therapy than when combination therapy is initiated following experience with one component medicine. The use of FDC products does not overcome this risk. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
149. Knowledge of Australian hospital pharmacists regarding delirium in elderly patients.
- Author
-
Kassie, Gizat M., Kalisch Ellett, Lisa M., Nguyen, Tuan A., and Roughead, Elizabeth E.
- Abstract
Abstract: Background: Delirium is a serious condition in which medications are just one of a number of potential predisposing or precipitating factors. Adequate knowledge of delirium among all healthcare professionals, including pharmacists, may assist in effective prevention and management. However, little is known about the knowledge of pharmacists regarding delirium. Aim: To assess Australian hospital pharmacists' knowledge of risk factors, symptoms, prevention and treatment of delirium in elderly patients. Method: A cross‐sectional survey was conducted via a web‐based questionnaire to collect information on participants' demographics, knowledge of delirium risk factors, symptoms, prevention and treatment. A link to the survey was included in the newsletters of The Society of Hospital Pharmacists of Australia, Australasian Delirium Association and New South Wales Therapeutic Advisory Group and distributed to hospital pharmacists in Australia via email. Results: One‐hundred and six responses from hospital pharmacists were available for analysis. Nine of 11 questions assessing basic knowledge were correctly answered by more than half of respondents. Seven of the eight questions related to delirium prevention strategies were correctly answered by more than half of pharmacists. However, only three of the eight questions about risk factors for delirium were answered correctly by more than half of pharmacists. Conclusion: Pharmacists' basic knowledge about delirium and prevention strategies was good; however, their knowledge of risk factors and symptoms of delirium needs to be improved. Delirium‐specific educational programs for pharmacists should be considered for improving their knowledge and understanding regarding delirium. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
150. Antipsychotic polypharmacy in older Australians.
- Author
-
Kalisch Ellett, Lisa M., Pratt, Nicole L., Kerr, Mhairi, and Roughead, Elizabeth E.
- Abstract
ABSTRACTBackground:Antipsychotics are commonly used, and the rate of use is highest, among those aged 65 years or over, where the risk of adverse events is also high. Up to 20% of younger adults use more than one antipsychotic concurrently; however there are few studies on the prevalence of antipsychotic polypharmacy in older people. We aimed to analyze antipsychotic use in elderly Australians, focusing on the prevalence of antipsychotic polypharmacy and the use of medicines to manage adverse events associated with antipsychotics.
Methods: A cross-sectional study was conducted using Australian Department of Veterans' Affairs (DVA) administrative claims data for the period 1 March 2014 to 30 June 2014. Veterans dispensed at least one antipsychotic medicine during the study period was included. We determined the number of participants dispensed antipsychotic polypharmacy and the number of participants dispensed medicines to manage antipsychotic side effects.Results: There were 7,412 participants with a median age of 86 years. Fifty-one percent (n=3,784) were women and 48% (n=3,569) lived in residential aged-care. Fifty one participants (0.7%) were dispensed anticholinergic medicines indicated for the management of antipsychotic-associated extrapyramidal movement disorders and eight (0.1%) were dispensed medicines for the management of hyperprolactinemia. Five percent of participants (n=365) received dual antipsychotics. Dual antipsychotic users were more likely to be under the care of a psychiatrist or to have had a mental health hospitalization than those using a single antipsychotic.Conclusions: Antipsychotic polypharmacy occurred in one in 20 elderly persons, indicating that there is room for improvement in antipsychotic use in elderly patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.